| |
2007 |
| June |
GlaxoSmithKline (GSK) launched a Phase 3 clinical trial evaluating its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in non-small cell lung cancer. The vaccine contains GSK’s proprietary adjuvant system, which includes Antigenics’ QS-21 Stimulon adjuvant, for which Antigenics will receive future milestone payments and product royalties upon successful development and commercialization. |
| May |
Antigenics presented end-of-study results from its Phase 3 trial of Oncophage in kidney cancer at the annual meeting of the American Urological Association. The study showed that Oncophage significantly prolonged recurrence-free survival and improved overall survival in a large subgroup of intermediate-risk patients. |
| April |
An oral presentation of updated data from a Phase 1/2 investigator-sponsored trial of Oncophage in recurrent, high-grade glioma was presented at the 75th annual meeting of the American Association of Neurological Surgeons. Preliminary results from the study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco, showed that Oncophage vaccination was associated with significant tumor-specific immune response in all 12 treated patients from baseline. |
| March |
Antigenics appoints Brian Corvese to the company’s board of directors. |
| |
2006 |
| December |
Antigenics appoints Peter Thornton and Timothy R. Wright to its board of directors. |
| November |
Preliminary data from a Phase 1/2 investigator-sponsored trial of Oncophage as a treatment for recurrent glioma are presented at the Immunotherapy Task Force Meeting, held at the Society of Neuro-Oncology’s 11th Annual Scientific Meeting. Preliminary results from the first cohort of six patients in the study, being conducted at the Brain Tumor Research Center at the University of California, San Francisco, showed that vaccination was associated with tumor-specific immune response in all six treated patients. |
| October |
Antigenics announces the sale of $25 million of convertible senior notes to a group of accredited investors. |
| September |
Antigenics appoints Hyam I. Levitsky, MD, to its board of directors. |
| |
Shalini Sharp succeeds Peter Thornton as Antigenics’ chief financial officer. |
| July |
Antigenics announces an expanded license and supply agreements for the use of QS-21 Stimulon® adjuvant with GlaxoSmithKline Biologicals, a vaccine division of GlaxoSmithKline (GSK). QS-21 is a key component included in several of GSK’s proprietary adjuvant systems. A number of GSK’s vaccine candidates currently under development are formulated with GSK’s proprietary adjuvant systems containing QS-21. |
| June |
Antigenics announces findings from an in-depth analysis of its Phase 3 study of Oncophage vaccine in kidney cancer. Review of the data at an international expert panel meeting on June 2, 2006, found that in the full analysis set, there was a clinically significant, 43-percent improvement in recurrence-free survival associated with Oncophage in a well defined subgroup of better-prognosis patients. |
|
Antigenics announces in an oral presentation at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) updated findings from a Phase 3 clinical trial of Oncophage in metastatic melanoma. In the study, patients who received at least 10 doses of vaccine experienced an extension in median survival of 29 percent compared with those who received physician’s choice. In a subset analysis, Oncophage was associated with a potentially clinically relevant benefit compared with physician’s choice for patients with stages IV M1a and M1b melanoma, if at least 10 doses of vaccine were administered. |
| March |
Antigenics announces top-line results from its Phase 3 study of Oncophage in kidney cancer patients who are at high risk of recurrence after surgery. The analysis was triggered based on the number of events (defined as recurrence of disease or death of a patient prior to recurrence) reported by study investigators. However, an independent review by the trial’s Clinical Events Committee revealed that a substantially smaller number of events had actually occurred. The preliminary analysis showed a trend in favor of Oncophage for recurrence-free survival (the study’s primary endpoint), and a trend against Oncophage for overall survival (secondary endpoint); both findings were not statistically significant. |
| |
2005 |
| November |
Bruce A. Leicher joins Antigenics as Vice President and General Counsel.
The Brain Tumor Research Center at the University of California, San Francisco, initiates a Phase 1/2, investigator-sponsored clinical trial of Oncophage as a treatment for patients with recurrent glioma.
|
| October |
Antigenics begins a Phase 1 trial of Aroplatin in solid tumors and B-cell lymphoma. Aroplatin, an investigational platinum agent, has been reformulated by Antigenics to enhance the drug’s activation and stability.
Antigenics initiates a Phase 1 trial of AG-707, an investigational vaccine designed to treat genital herpes.
Jill M. Forrest joins Antigenics as Vice President of Marketing and Sales.
Antigenics announces survival data from a preliminary analysis of the Phase 3 trial of Oncophage in metastatic melanoma. The study showed that in all randomized stage IV M1a patients median survival improved by more than 50 percent in the Oncophage-treated arm compared with those in the physician’s choice treatment arm. A final data analysis is expected during the first quarter of 2006. |
| June |
Antigenics announces that Oncophage® (vitespen; formerly HSPPC-96) has been granted orphan drug status for the treatment of renal cell carcinoma by the European Medicines Agency (EMEA). |
| May |
A publication in Nature Immunology provides support for the immunological mechanism of action of the company’s heat shock protein (HSP)-based vaccines. The paper demonstrates that complexes of HSPs and peptides are the necessary and sufficient form of antigen to activate a killer T-cell immune response in vivo. |
| January |
Antigenics completed a private placement of convertible senior notes due 2025 to third-party investors, raising net proceeds of approximately $48 million. |
| |
2004 |
| September |
Antigenics appoints Alastair J. J. Wood to the company’s board of directors. |
| July |
Roman M. Chicz, PhD, is appointed senior vice president of research and preclinical development, a newly created position at Antigenics. |
| June |
Demographic data from the company’s Phase 3 trial of Oncophage in renal cell carcinoma, being conducted by The Antigenics Renal Cell Carcinoma Study Group, were published at the 40th annual meeting of the American Society of Clinical Oncology (ASCO). Also presented were immunological findings from a Phase 2 trial of combination treatment with Oncophage and cytokines in metastatic melanoma. |
| May |
Antigenics announces that Peter Thornton will join the company as chief financial officer and senior vice president. Jeff Clark, who has been CFO since March 2003, has resigned, with plans to return to his home state of Texas. |
| March |
Antigenics announces the sale of its manufacturing rights for feline leukemia virus vaccine to French veterinary pharmaceutical manufacturer Virbac S.A. for $14.25 million in cash. |
| February |
Underwriters of Antigenics’ public offering
in January 2004 purchase 400,000 shares of common stock
pursuant to a partial exercise of their over-allotment option.
Net proceeds to Antigenics from the sale of the additional
shares are approximately $4 million. |
| January |
Antigenics completes $52.5 million public
offering of common stock. |
| |
2003 |
| December |
An independent Data Monitoring Committee
convenes as scheduled for the interim analysis of the Phase
3 trial of Oncophage
in renal cell carcinoma,
and recommends that the trial proceed as planned. The DMC
states that there is no need to change the patient accrual
goals and declares the design and conduct of the trial sound. |
| |
Data on heat
shock protein-based vaccines were presented in a separate
poster sessions at the 45th annual meeting of the American
Society of Hematology. Preliminary findings from a Phase
1 study of HSPPC-70, an HSP70-based cancer vaccine, in chronic
myelogenous leukemia and from a Phase 2 trial of Oncophage
in non-Hodgkins lymphoma indicate that treatment with
the HSP-based vaccines is well tolerated and feasible, and
may be associated with clinical response. |
| November |
The US Food and Drug Administration lifts
the partial clinical hold on Phase 3 clinical
trials of Oncophage,
and Antigenics resumes patient enrollment for the studies.
The agencys decision to lift the hold came 13 weeks
after its request for product characterization information
in September 2003. |
| |
Renu Gupta,
MD, joins the company as senior vice president of development.
Elma S. Hawkins, PhD, is appointed to senior advisor, and
Jonathan J. Lewis, MD, PhD, leaves the company. |
| October |
Antigenics publishes immunological results
from Phase 2 trials evaluating Oncophage
in the treatment of both advanced melanoma
and colorectal
cancer in the Journal of Immunology. Significant
cancer-specific immune response among patients receiving
Oncophage was observed, and the immunological mechanism
of action was determined to be the same for both melanoma
and colorectal cancer. |
| September |
The US Food and Drug Administration declares
a partial clinical hold on Phase 3 clinical
trials of Oncophage,
stating product characterization issues needed to be more
fully documented. |
| |
Antigenics presented results from a Phase
1 trial of Oncophage
in patients with nonmetastatic pancreatic
cancer in an oral presentation at the annual European
Cancer Conference (ECCO 12). Patients in the pilot study,
which included 10 evaluable patients, experienced a median
overall survival of 2.5 years, with one patient still alive
and disease-free after five years, and two other patients
alive and disease-free 2.1 years after treatment. |
| August |
Clinical Cancer Research published
results from a Phase 2 trial of Oncophage
for treatment of colorectal
cancer as a featured article in the August 15 issue.
In the study, more than half of the 29 patients who received
Oncophage demonstrated significant immunological response
- which not only appeared to be correlated with clinical
response but also found to be an independent factor for
prognosis. |
| June |
In an oral presentation at the 39th annual
meeting of the American Society of Clinical Oncology (ASCO),
Antigenics presented updated results from a pilot study
of HSPPC-70, an HSP70-based cancer vaccine, in combination
treatment of chronic myelogenous
leukemia. Responses were observed in seven of the eight
patients evaluated. |
| |
Antigenics also presented at ASCO findings
from two Phase 2 studies, which demonstrated that treatment
with Oncophage was associated with clinical and immunological
response in both kidney
cancer and non-Hodgkin’s lymphoma. |
| April |
Antigenics initiates a large, multicenter
Phase 2 trial of AG-858 in combination treatment for chronic
myelogenous leukemia. |
| March |
Antigenics appoints three new members, Margaret
Eisen, Wadih Jordan
and Mark Kessel, to its board of directors. Jeff D. Clark promoted to chief financial officer. |
| January |
Antigenics completes $62 million public offering
of common stock. |
| |
2002 |
| December |
Nine new heat shock protein (HSP)-related
patents are issued, expanding
Antigenics HSP intellectual property portfolio to
45 US-issued patents. |
|
Antigenics reports significant results from
a pilot study of HSPPC-70, an HSP70-based cancer vaccine,
in combination treatment with Gleevec in chronic
myelogenous leukemia patients. |
| October |
Antigenics files an opposition to a European
patent licensed to Stressgen Biotechnologies on grounds
that its claimed invention is obvious, lacks novelty, is
insufficiently described, and encompasses non-patentable
subject matter. |
| |
The peer-reviewed Journal of Clinical
Oncology publishes results from a Phase 2 trial of Oncophage
in metastatic melanoma.
In the study, Oncophage treatment was associated with both
immunological and clinical response, and no treatment-related
toxicity was observed. |
| July |
Antigenics expands its HSP
technology platform with 15 patents, allowing Antigenics
core technology to be applied in novel applications in a
broader range of disease areas. |
| |
Deanna Petersen joins Antigenics as vice
president of business development. |
| |
The US Food and Drug Administration (FDA)
grants Oncophage orphan
drug status in metastatic melanoma. The designation
provides Antigenics with potential market exclusivity in
metastatic melanoma for seven years from FDA marketing approval. |
| |
Antigenics begins trial of Aroplatin
monotherapy in metastatic colorectal
cancer. |
| |
Frank
V. AtLee III, chairman of Monsanto Company, appointed
to Antigenics board of directors. |
| |
Antigenics CEO Garo
Armen named chairman of Elan Corporation. |
| June |
CEO Garo Armen wins NYC Biotechnology Entrepreneur
of the Year award from Ernst & Young. |
| |
A study published in Urologic Oncology
demonstrates improved quality of life in kidney
cancer patients receiving Oncophage treatment. |
| May |
Antigenics receives orphan drug status from
the FDA for Oncophage in renal cell carcinoma, providing
the company with potential market exclusivity for seven
years from FDA marketing approval. |
| |
Antigenics presents promising interim results
from trials of Oncophage in metastatic melanoma, colorectal
and gastric
cancers at the annual ASCO scientific sessions. |
| |
First patient is enrolled into Antigenics
pivotal Phase 3 trial of Oncophage as a treatment for metastatic
melanoma. |
| April |
Antigenics presents positive clinical and
immunological data of Oncophage in melanoma and colorectal
cancer at the annual meeting of the American Association
for Cancer Research (AACR). |
| February |
Oncophage receives fast
track designation from the FDA for treatment of metastatic
melanoma. This is the second fast track designation for
Oncophage, which previously received the designation as
a treatment of renal cell carcinoma. |
| January |
Russell
Herndon named president and chief operating officer. |
| |
Antigenics completes $60 million public offering
of common stock. |
| |
|
| |
2001 |
| October |
Oncophage
becomes the first patient-specific cancer product to receive
FDA fast
track designation. |
| September |
Antigenics elects Samuel D.
Waksal, CEO of ImClone Systems, to the board of directors
(resigned June 2002). |
| July |
Antigenics and Bruce Walker
of Massachusetts General Hospital test HSP-based approach
to HIV. |
| Acquisition of Aronex Pharmaceuticals
is completed. |
| QS-21
adjuvant demonstrates a clinical response in Alzheimers
disease, according to a study conducted by Elan Pharmaceuticals
and American Home Products. |
| May |
Antigenics presents Oncophage
data from melanoma
and colorectal
cancer clinical trials at ASCO. |
| April |
Acquisition of Aronex Pharmaceuticals
is announced. |
| Antigenics receives National
Institutes of Health grant for malaria
study using QS-21 technology. |
| February |
Antigenics launches Phase 1
study of AG-702 for genital
herpes. |
| January |
Six patents
are issued that expand Antigenics ability to treat
cancers and infectious diseases. |
| Hiring of Russell Herndon as
chief operating officer is announced. |
| |
|
| |
2000 |
| November |
Oncophage
pancreatic
cancer trial is expanded at Memorial Sloan-Kettering
Cancer Center. |
| Acquisition of Aquila Biopharmaceuticals
is completed. |
| Antigenics wins European patent
dispute with Stressgen relating to the use of HSPs for treatment
of cancer and infectious diseases. |
| October |
Antigenics launches Phase 2
clinical trial of Oncophage for treatment of sarcoma at Memorial Sloan-Kettering Cancer Center. |
| July |
CD91 heat shock protein receptor is discovered. |
| June |
Antigenics launches first Phase
3 trial, a study of Oncophage in renal
cell carcinoma. |
| May |
Antigenics presents results
of clinical trials in renal cell carcinoma and gastric
cancer at ASCO scientific sessions. |
| April |
Patent
is issued for the use of HSPs in infectious diseases. |
| Antigenics presents clinical
data from Oncophage melanoma
trial at the annual meeting of the American Association
for Cancer Research. |
| March |
Antigenics launches Phase 2
clinical trial of Oncophage for the treatment of non-Hodgkins
lymphoma. |
| Patents are issued to Antigenics
in the field of functional genomics. |
| February |
Antigenics raises $72.5 million
in initial public offering of common stock. |
| January |
Patent is issued covering the
treatment of autoimmune diseases with HSPs. |
| |
|
| |
1999 |
| November |
Antigenics raises $39.2 million
in a round of private financing. |
| October |
Patent
is issued for HSP-based vaccine delivery technology. |
| May |
Antigenics opens state-of-the-art
research and development/manufacturing facility in Woburn,
Massachusetts. |
| Antigenics presents Oncophage
data in renal
cell carcinoma at ASCO annual meeting. |
| January |
Antigenics raises $27.6 million
in round of private financing. |
| |
|
| |
1998 |
| 4Q |
Antigenics launches Phase 2
trial of Oncophage
in melanoma
and colorectal
cancer in Milan. |
| November |
Patent
is issued for use of HSPs in combination with adoptive immunotherapy. |
| October |
Antigenics establishes autologous
cancer vaccine with Sigma Tau, Italys second largest
pharmaceutical company. |
| May |
Patent is issued for the use
of HSPs in the treatment of cancer. |
| |
|
| |
1997 |
| November |
Phase 1 trial of Oncophage
for treatment of pancreatic
cancer commences at Memorial Sloan-Kettering Cancer
Center. |
| |
|
| |
1996 |
| December |
Antigenics raises $10.6 million
in round of private financing. |
| November |
Investigational new drug application
is filed with the FDA for Oncophage
in cancer. |
| |
|
| |
1995 |
| December |
Antigenics raises $1.5 million
in round of private financing. |
| |
|
| |
1994 |
| March |
Founding of Antigenics |